Oleg Fedorov
University of Oxford
H-index: 66
Europe-United Kingdom
Top articles of Oleg Fedorov
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3 | Bioorganic & Medicinal Chemistry Letters | Brigitt Raux Karly A Buchan James Bennett Thomas Christott Matthew S Dowling | 2024/1/15 |
Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist | Journal of Medicinal Chemistry | Esra Balıkçı Anne-Sophie MC Marques Ludwig G Bauer Raina Seupel James Bennett | 2024/4/18 |
Imidazo [1, 2-b] pyridazines as inhibitors of DYRK kinases | European Journal of Medicinal Chemistry | Scott H Henderson Fiona J Sorrell James M Bennett Oleg Fedorov Marcus T Hanley | 2024/4/5 |
Fluorescence assay for MERS-CoV Mpro activity measurement | Charline Giroud Oleg Fedorov | 2024/4/26 | |
Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor | Journal of medicinal chemistry | Yan Xiong Holger Greschik Catrine Johansson Ludwig Seifert Vicki Gamble | 2024/3/27 |
Fluorescence assay for Enterovirus coxsackievirus A16 2A protease activity measurement | Charline Giroud Oleg Fedorov | 2024/4/26 | |
Efficient large-scale exploration of fragment hit progression by exploiting binding-site purification of actives (B-SPA) through combining multi-step array synthesis and HT … | Harold Grosjean Anthony Aimon Storm Hassell-Hart Warren Thompson Lizbé Koekemoer | 2024/2/9 | |
Novel Inhibitors of MLLT1/3, a Critical Component of the Super-Elongation Complex (SEC), Target a Range of Molecularly Defined Acute Leukemias, with a Differential Profile to … | Blood | John Pollard Graham Craggs Gillian Farnie Matthew Fawkes Oleg Fedorov | 2023/11/28 |
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors | Science | Melissa L Boby Daren Fearon Matteo Ferla Mihajlo Filep Lizbé Koekemoer | 2023/11/10 |
Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors | Pathogens | Marion Schuller Tryfon Zarganes-Tzitzikas James Bennett Stephane De Cesco Daren Fearon | 2023/2/15 |
EMT-like Activation in CLL Provides Novel Therapeutic Target | Blood | Charlott Repschlaeger Mariette Odabashian Filomena Spada Zamzam Almutairi John G Gribben | 2022/11/15 |
Discovery of high-affinity small-molecule binders of the epigenetic reader YEATS4 | Journal of medicinal chemistry | Allyn T Londregan Karlygash Aitmakhanova James Bennett Laura J Byrnes Daniel P Canterbury | 2022/12/23 |
Discovery of a potent dual SLK/STK10 inhibitor based on a maleimide scaffold | Journal of Medicinal Chemistry | Ricardo AM Serafim Fiona J Sorrell Benedict-Tilman Berger Ross J Collins Stanley NS Vasconcelos | 2021/8/31 |
Discovery and characterization of selective and ligand-efficient DYRK inhibitors | Journal of Medicinal Chemistry | Scott H Henderson Fiona Sorrell James Bennett Oleg Fedorov Marcus T Hanley | 2021/8/3 |
Controlling intramolecular interactions in the design of selective, high-affinity ligands for the CREBBP bromodomain | Journal of medicinal chemistry | Michael Brand James Clayton Mustafa Moroglu Matthias Schiedel Sarah Picaud | 2021/7/13 |
Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking | Science advances | Marion Schuller Galen J Correy Stefan Gahbauer Daren Fearon Taiasean Wu | 2021/4/14 |
Ipomoeassin-F inhibits the in vitro biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor (preprint) | Peristera Roboti Kwabena B Duah Guanghui Zong Hayden Schneider Wei Q Shi | 2020 | |
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors | BioRxiv | COVID Moonshot Consortium Hagit Achdout Anthony Aimon Dominic S Alonzi Robert Arbon | 2020/10/30 |
Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics (preprint) | H Achdout A Aimon E Bar-David H Barr A Ben-Shmuel | 2020 | |
COVID moonshot: open science discovery of SARS-CoV-2 main protease inhibitors by combining crowdsourcing, high-throughput experiments, computational simulations, and machine … | BioRxiv | Hagit Achdout Anthony Aimon Elad Bar-David GM Morris | 2020/10/30 |
